A Semi-Mechanistic Mathematical Model of Immune Tolerance Induction to Support Preclinical Studies of Human Monoclonal Antibodies in Rats
Open Access
- 27 June 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (7) , 845
Abstract
Background/Objectives: The administration of human monoclonal antibodies (mAb) in preclinical pharmacokinetics and toxicology studies often triggers an immune response, leading to the formation of anti-drug antibodies (ADA). To mitigate this effect, we have recently performed and reported on studies using short-term immunosuppressive regimens to induce prolonged immune tolerance towards a human mAb, erenumab, in rats. Here, we report on the development of a semi-mechanistic modeling approach that quantitatively integrates pharmacokinetic and immunogenicity assessments from immune tolerance induction studies to provide a framework for the simulation-based evaluation of different immune induction scenarios for the maintenance of prolonged immune tolerance towards human mAbs. Methods: The integrated pharmacokinetic/pharmacodynamic (PK/PD) modeling approach combined a semi-mechanistic model of the adaptive immune system to predict ADA formation kinetics with a population pharmacokinetic model to assess the impact of the time course of the ADA magnitude on the PK of erenumab in rats. Model-derived erenumab concentration–time profiles served as input for a quantitative system pharmacology-style semi-mechanistic model of the adaptive immune system to conceptualize the ADA response as a function of the kinetics of CD4+ T helper cells and T regulatory cells. Results: The model adequately described the observed ADA magnitude–time profiles in all treatment groups and reasonably simulated the kinetics of selected immune cells responsible for ADA formation. It also successfully captured the impact of tacrolimus/sirolimus immunomodulation on ADA formation, demonstrating that the regimen effectively suppressed ADA formations and induced immune tolerance. Conclusions: This work demonstrates the utility of modeling approaches to integrate pharmacokinetic and immunogenicity assessment data for the prospective planning of long-term toxicology studies to support the preclinical development of mAbs.Keywords
Funding Information
- University of Tennessee Health Science Center and Merck Sharp & Dohme LLC
This publication has 86 references indexed in Scilit:
- A Model‐Based Approach to Quantify the Time‐Course of Anti‐Drug Antibodies for Therapeutic ProteinsClinical Pharmacology & Therapeutics, 2018
- Pharmacokinetics of Monoclonal AntibodiesCPT: Pharmacometrics & Systems Pharmacology, 2017
- Pharmacokinetics, pharmacodynamics and toxicities of methotrexate in healthy and collagen‐induced arthritic ratsBiopharmaceutics & Drug Disposition, 2013
- Subcutaneous Absorption of Monoclonal Antibodies: Role of Dose, Site of Injection, and Injection Volume on Rituximab Pharmacokinetics in RatsPharmaceutical Research, 2011
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitisEuropean Journal of Clinical Pharmacology, 2009
- Towards a consensus on datasets and evaluation metrics for developing B‐cell epitope prediction toolsJournal of Molecular Recognition, 2007
- Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applicationsImmunogenetics, 2005
- Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profilesImmunogenetics, 2004
- Proliferative Assays for T Cell FunctionCurrent Protocols in Immunology, 2004
- A Model of the Immune Network with B-T Cell Co-operation. II—The Simulation of OntogenesisJournal of Theoretical Biology, 1996